Investigational drug · Phase 2
NS-863
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "NS-863"
First trial start
2026
Sep 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NS-863", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Pulmonary Arterial Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "NS-863" as an intervention, largest first.
- A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
NS Pharma, Inc.Industry
NCT07441278 · 177 participants (planned) · Start Sep 28, 2026 · Primary completion Sep 14, 2028
Drug: NS-863 Low Dose; NS-863 High Dose · For: Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Sites: Knoxville, Tennessee; Kitakyushu, Japan
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingRecruiting
NS Pharma, Inc.Industry
NCT07441200 · 135 participants (planned) · Start Sep 29, 2026 · Primary completion Aug 1, 2028
Drug: NS-863 Low Dose; NS-863 High Dose and 1 more · For: Pulmonary Arterial Hypertension
Sites: Kitakyushu, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.